Finally out! Thank you to all the participating centers and operators!!
Balloon-Assisted Translocation of the Mitral Anterior Leaflet to Prevent Outflow Tract Obstruction During TMVR: BATMAN-Registry | JACC: Cardiovascular Interventions https://t.co/8oF6aF3VyI
5 patients enrolled and treated today in Structural Heart trials at @MontefioreNYC , including the first 3 US patients in PARADIGM: the @AnterisTech DurAVR THV RCT. DurAVR is a biomimetic balloon-expandable valve designed to restore laminar flow in severe AS.
@MonteHeart
Together with @Antocol17 and @azeemlatib, we comment on @JACCJournals how real-time fluoroscopic assessment can uncover suboptimal valve expansion and why this may matter for long-term TAVR durability
https://t.co/MBftdI7uce
https://t.co/pae1nLO5CT
It’s the final day of @TCTMD 2025! We have enjoyed connecting with colleagues from around the world and are looking forward to hearing these podium presentations today.
🗓️ Tuesday, October 28
8:40 AM – Computational Fluid Dynamic and Morphometric Analysis of the Novel DynamX® Bioadaptor System at Baseline and 1-Year Follow-Up (@giuliorus)
📍Presentation Theater 2 | Hall D
Session: Cases with the Masters – Acute Coronary Syndromes: Vulnerable Plaque
12:00 PM – DynamX® Bioadaptor Implantation for Treatment of Complex Coronary Artery Disease – Final Results from the DYNAMITE Study (@leoneppmd)
📍Station 5 | Halls B-C
Session: Scientific Abstracts – Newer Stent Design Studies
1:00 PM – 2-Year Nationwide Analysis from SWEDEHEART: Comparison of Drug-Coated Balloons and the Bioadaptor in Treatment of De Novo Coronary Lesions @DavidErlinge)
📍Station 7 | Halls B-C
Session: Novel Technologies for Transcatheter Coronary Interventions
#TCT2025 #Cardiology #Bioadaptor #LithiX #PCI #Innovation #ElixirMedical
Do female patients respond differently than males? Higher 2-year MACE after sirolimus-coated balloon angioplasty for female patients with in-stent restenosis. A hypothesis generating research letter @Dr.LucaTesta @leoneppmd@AGrecoMD@Dari08s
https://t.co/oSMRqCSJo1
What’s next in HF, amyloid, HCM, valvular therapies, shock, and next-gen LVADs? 🤔
🎓 Join #MonteHeart2025 to hear from and 🤝 with @MonteHeart faculty and special guests!
🗓️ June 12–13 @MontefioreNYC + Livestream 📺
⤵️ Scan the QR or tap the link in comments to register!
Let the #JOURNEY begin! 🚀
We are thrilled to announce our first #TAVR case at @MonteHeart as part of the JOURNEY pivotal study - a major step in pushing boundaries for #AR care.
A shoutout to our incredible Team for making this possible @azeemlatib@EdwinHoMD